Incruse Ellipta (GlaxoSmithKline LLC)
Welcome to the PulseAid listing for the Incruse Ellipta drug offered from GlaxoSmithKline LLC. This Anticholinergic [EPC],Cholinergic Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | GlaxoSmithKline LLC |
| NON-PROPRIETARY NAME: | umeclidinium |
| SUBSTANCE NAME: | UMECLIDINIUM BROMIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Anticholinergic [EPC],Cholinergic Antagonists [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | AEROSOL, POWDER |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2014-04-30 |
| END MARKETING DATE: | 0000-00-00 |
Incruse Ellipta HUMAN PRESCRIPTION DRUG Details:
| Item Description | Incruse Ellipta from GlaxoSmithKline LLC |
| LABELER NAME: | GlaxoSmithKline LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 62.5(ug/1) |
| START MARKETING DATE: | 2014-04-30 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0173-0873_1b9451c9-5180-475e-add7-87294ad92252 |
| PRODUCT NDC: | 0173-0873 |
| APPLICATION NUMBER: | NDA205382 |
Other UMECLIDINIUM BROMIDE Pharmaceutical Manufacturers / Labelers:
